open access

Vol 52, No 1 (2018)
Review article
Submitted: 2017-08-21
Get Citation

Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option

Piotr Janik, Natalia Szejko
DOI: 10.1016/j.pjnns.2017.10.015
·
Neurol Neurochir Pol 2018;52(1):84-87.

open access

Vol 52, No 1 (2018)
Review article
Submitted: 2017-08-21

Abstract

Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)1A receptor partial agonist and 5-HT2A receptor antagonist primarily used for the treatment of schizophrenia, bipolar disorder or depression with psychotic ideation. However, recently a number of new possible indications have been suggested, among them Gilles de la Tourette syndrome (GTS). In two randomized, double-blind, placebo-controlled studies in children and adolescents with GTS has been confirmed the efficacy of aripiprazole in tic reduction. In comparison to other neuroleptics, aripiprazole seems to be similarly effective. What is more, the number and profile of possible adverse effects is also favorable. As a consequence, aripiprazole had been registered by Food and Drug Administration (FDA) for the treatment of tics and represents new therapeutic option in treatment of GTS.

Abstract

Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)1A receptor partial agonist and 5-HT2A receptor antagonist primarily used for the treatment of schizophrenia, bipolar disorder or depression with psychotic ideation. However, recently a number of new possible indications have been suggested, among them Gilles de la Tourette syndrome (GTS). In two randomized, double-blind, placebo-controlled studies in children and adolescents with GTS has been confirmed the efficacy of aripiprazole in tic reduction. In comparison to other neuroleptics, aripiprazole seems to be similarly effective. What is more, the number and profile of possible adverse effects is also favorable. As a consequence, aripiprazole had been registered by Food and Drug Administration (FDA) for the treatment of tics and represents new therapeutic option in treatment of GTS.

Get Citation

Keywords

Gilles de la Tourette syndrome, Aripiprazole, Randomized double-blind placebo-controlled study

About this article
Title

Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 52, No 1 (2018)

Pages

84-87

DOI

10.1016/j.pjnns.2017.10.015

Bibliographic record

Neurol Neurochir Pol 2018;52(1):84-87.

Keywords

Gilles de la Tourette syndrome
Aripiprazole
Randomized double-blind placebo-controlled study

Authors

Piotr Janik
Natalia Szejko

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl